CompletedNot Applicable

A New Marker for Early Diagnosis of Pneumoperitoneum-Related Acute Kidney Injury: Insulin-Like Growth Factor-1 (IGF-1)

Turkey (Türkiye)25 participantsStarted 2023-02-08

Plain-language summary

In our study, to show the effect of pneumoperitoneum on acute kidney injury in patients scheduled for laparoscopic surgery, NGAL and IGF-1 values will be measured before, after and 24 hours after pneumoperitoneum, and these values will be compared. In our study, we aimed to investigate the effect of pneumoperitoneum applied on acute kidney injury in patients who underwent laparoscopic surgery. Creatinine and NGAL have been used successfully in the follow-up of acute kidney injury. Our study investigates whether IGF-1 will be an effective indicator in acute kidney injury by comparing IGF-1 and NGAL values before pneumoperitoneum, after pneumoperitoneum and at the postoperative 24th hour.

Who can participate

Age range

18 Years – 70 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients aged 18-70 years of both sexes * ASA I-III Patients Exclusion Criteria: * Obesity, * Chronic Kidney Disease, * Chronic Renal Failure, * Acute Renal Failure, * Peripheral and ischemic vascular disease, * Chronic Heart Failure, * History of anaphylaxis, * A-V block, * Creatinine level \>1.4, * Neuromuscular disease, * Malignant hypertension, * Pyelonephritis, * Urinary tract infectio, * Severe inflammation/possible sepsis, * Active malignancy, * Patients with surgery reversion to laparotomy, * Hemodynamic instability, need for vasopressors, * Severe bleeding requiring blood transfusion,

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Diagnosis of acute kidney injury in the early postoperative period with IGF-1 (insulin like growth factor-1)

Timeframe: before pneumoperitoneum, after pneumoperitoneum, and at the postoperative 24th hour.

Trial details

NCT IDNCT05612802

SponsorBaskent University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-03-30

View on ClinicalTrials.gov More Acute Kidney Injury (Nontraumatic) trials